#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal squamous cell carcinoma stage III Hyperoxaluria Usher's syndrome Necrotising enterocolitis neonatal Cataract Craniopharyngioma Haemophilia A without inhibitors Non-Hodgkin's lymphoma unspecified histology indolent Atypical haemolytic uraemic syndrome Chronic graft versus host disease in intestine B-cell lymphoma recurrent Ichthyosis Liver abscess Keratosis follicular Ureteric cancer More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis II – Trials in Disease Retinoblastoma Haemophilia A with anti factor VIII – Diagnostics Testicular leiomyosarcoma – Treatment Thrombotic thrombocytopenic purpura – Basic Information Pituitary-dependent Cushing’s syndrome – Basic Information Congenital generalised lipodystrophy Vascular malformation – Basic Information Primary mediastinal large B-cell lymphoma – Treatment Nephroblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Epinephrine SPY002 Pentoxifylline Lerodalcibep Crisantaspase Vo659 Permethrin Gad20-209-Fsp-A3 Voxelotor HSP-CAR19M Arbaclofen Omaveloxolone LTX-002 SODIUM Palivizumab Ivospemin [18F]CPFPX Axatilimab Lutetium (177Lu) Edotreotide Clavulanic Acid Lenacapavir More therapies…

    Learn about Your Condition

    Mantle cell lymphoma Arthritis infective Pseudomyxoma peritonei Vaginal infection Partial seizures Osteomyelitis Psoriasis Dementia Conjunctivitis allergic Anxiety Hyperlipidaemia Cutaneous sarcoidosis Lysosomal storage disorder Left ventricular dysfunction Primary hyperoxaluria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6

  • Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Op-1250
    • PALAZESTRANT
    • Anastrozole
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Belgium Czechia Denmark Finland France Germany +7

  • Durvalumab Maintenance Therapy for Frail Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Durvalumab
    France

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6

  • Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Olaparib
    Austria France Germany Poland Romania Spain

  • Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Capecitabine
    • Docetaxel
    • Lenvatinib
    Denmark France Norway Portugal Romania Spain

  • Study on the Effectiveness and Safety of L19TNF and Dacarbazine for Patients with Advanced or Metastatic Soft-Tissue Sarcoma After Previous Treatments

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Dacarbazine
    • Onfekafusp Alfa
    France Germany Italy Poland Spain

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France
Previous Page
1 … 14 15 16 17 18 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!